Review Article
Volume 12 Issue 8 - 2020
Brain, Diabetes and Cognition
Edgardo Gabriel Reich1*, Beatriz Elena Halac1, Lina Osorio Coy1 and Patricia Castaño2
1Department of Neurology, Hospital Dr. Julio Mendez, Instituto de Neurociencias, Universidad Maimonides, Universidad de Buenos Aires,
2Department of Diabetes and Nutrition, Hospital C.G. Durand, Buenos Aires, Argentina
*Corresponding Author: Edgardo Gabriel Reich, Department of Neurology, Hospital Dr. Julio Mendez, Instituto de Neurociencias, Universidad Maimonides, Universidad de Buenos Aires, Argentina.
Received: June 17, 2020; Published: July 22, 2020




Abstract

Diabetes mellitus (DM) is a chronic metabolic disease, characterized mainly by elevated levels of blood glucose, associated with other important metabolic disturbances. Prevalence of DM is dramatically increasing worldwide, but especially in western countries, due to several factors as like diet, lifestyle and population aging.

Recent studies demonstrate that some diabetic patients have an increased risk of developing cognitive decline and dementia compared with healthy individuals. Although this may reflect brain changes as a consequence of diabetes, the coexistence of diabetes and cognitive dysfunction suggest common risk factors and causative mechanisms.

Cognitive dysfunction, including mild cognitive impairment and dementia, is increasingly recognized as an important comorbidity and complication of diabetes that affects patient’s health and diabetes management with several public health implications. The aim of our work is to give an overview of cognitive dysfunction in people with diabetes, describing its clinical features and their biochemical basis and future perspectives.

Keywords: Diabetes Mellitus (DM); Diet; Lifestyle; Population Aging

References

  1. American Diabetes Association Standards of medical care in diabetes-2019: section 12. Older adults”. Diabetes Care1 (2019): S139-S147.
  2. International Diabetes Federation (IDF) (2017) IDF diabetes atlas, 8th edition (2017).
  3. Prince M., et al. “The global prevalence of dementia: a systematic review and metaanalysis”. Alzheimers Dement1 (2013): 63-75.
  4. International Diabetes Federation. IDF diabetes atlas. 7. Brussels: International Diabetes Federation (2015).
  5. Hebert LE., et al. “Alzheimer disease in the United States (2010- 2050) estimated using the 2010 census”. Neurology19 (2013): 1778-1783.
  6. Alzheimer's Association. “2016 Alzheimer's disease facts and figures”. Alzheimer's and Dementia4 (2016): 459-509.
  7. Biessels GJ and Whitmer RA. “Cognitive dysfunction in diabetes: how to implement emerging guidelines”. Diabetologia 1 (2020): 3-9.
  8. Sridhar GR., et al. “Emerging links between type 2 diabetes and Alzheimer's disease”. World Journal of Diabetes 5 (2015): 744-751.
  9. Moheet A., et al. “Impact of diabetes on cognitive function and brain structure”. Annals of the New York Academy of Sciences 1353 (2015): 60-71.
  10. Wild S., et al. “Global prevalence of Diabetes: Estimates for the year 2000 and projections for 2030”. Diabetes Care 27 (2004): 1047-1053.
  11. Cukierman-Yaffe T., et al. “Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: the action to control cardiovascular risk in diabetes-memory in diabetes (ACCORD-MIND) trial”. Diabetes Care 32 (2009): 221-226.
  12. Biessels GJ and Despa F. “Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications”. Nature Reviews Endocrinology 10 (2018): 591-604.
  13. Rawlings AM., et al. “Diabetes in midlife and cognitive change over 20 years: a cohort study”. Annals of Internal Medicine 11 (2014): 785-793.
  14. Chatterjee S., et al. “Type 2 diabetes as a risk factor for dementia in women compared with men: a pooled analysis of 2.3 million people comprising more than 100,000 cases of dementia”. Diabetes Care2 (2016): 300-307.
  15. Li W., et al. “Type 1 diabetes mellitus and cognitive impairments: a systematic review”. Journal of Alzheimer's Disease 1 (2017): 29-36.
  16. Palta P., et al. “Magnitude of cognitive dysfunction in adults with type 2 diabetes: a meta-analysis of six cognitive domains and the most frequently reported neuropsychological tests within domains”. Journal of the International Neuropsychological Society 3 (2014): 278-291.
  17. Petersen RC., et al. “Practice guideline update summary: mild cognitive impairment: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology”. Neurology 90 (2018): 126-135.
  18. Smolina K., et al. “Risk of dementia in patients hospitalised with type 1 and type 2 diabetes in England, 1998-2011: a retrospective national record linkage cohort study”. Diabetologia5 (2015): 942-950.
  19. Zilliox LA., et al. “Diabetes and Cognitive Impairment”. Current Diabetes Reports 9 (2016): 87.
  20. Pal K., et al. “Mild cognitive impairment and progression to dementia in people with diabetes, prediabetes and metabolic syndrome: a systematic review and meta-analysis”. Social Psychiatry and Psychiatric Epidemiology 11 (2018): 1149-1160.
  21. Biessels GJ., et al. “Risk of dementia in diabetes mellitus: a systematic review”. The Lancet Neurology 1 (2006): 64-74.
  22. McCrimmon RJ., et al. “Diabetes and cognitive dysfunction”. Lancet 379 (2012): 2291-2299.
  23. Jacobson AM., et al. “Biomedical risk factors for decreased cognitive functioning in type 1 diabetes: an 18 year follow-up of the Diabetes Control and Complications Trial (DCCT) cohort”. Diabetologia 54 (2011): 245-255.
  24. Bogush M., et al. “Blood Brain Barrier Injury in Diabetes: Unrecognized Effects on Brain and Cognition”. Journal of Neuroimmune Pharmacology 4 (2017): 593-601.
  25. Brands AM., et al. “The effects of type 1 diabetes on cognitive performance: a meta-analysis”. Diabetes Care 28 (2005): 726-735.
  26. Lin MT and Beal MF. “Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases”. Nature7113 (2006): 787-795.
  27. Kroner Z. “The relationship between Alzheimer's disease and diabetes: type 3 diabetes?” Alternative Medicine Review4 (2009): 373-379.
  28. Tumminia A., et al. “Type 2 Diabetes Mellitus and Alzheimer's Disease: Role of Insulin Signalling and Therapeutic Implications”. International Journal of Molecular Sciences 11 (2018): 3306.
  29. De la Monte SM and Tong M. “Brain metabolic dysfunction at the core of Alzheimer's disease”. Biochemical Pharmacology4 (2014): 548-559.
  30. Mittal K and Katare DP. “Shared links between type 2 diabetes mellitus and Alzheimer's disease: a review”. Diabetes and Metabolic Syndrome: Clinical Research and Reviews2 (2016): S144-S149.
  31. Hoozemans JJ., et al. “The unfolded protein response is activated in Alzheimer's disease”. Acta Neuropathologica 2 (2005): 165-172.
  32. Nijholt DA., et al. “The unfolded protein response is associated with early tau pathology in the hippocampus of tauopathies”. The Journal of Pathology5 (2012): 693-702.
  33. Jackson K., et al. “Amylin deposition in the brain: a second amyloid in Alzheimer disease?” Annals of Neurology4 (2013): 517-526.
  34. Kandimalla R., et al. “Is Alzheimer's disease a type 3 diabetes? A critical appraisal”. Biochimica et Biophysica Acta - Molecular Basis of Disease 5 (2017): 1078-1089.
  35. Launer LJ., et al. “Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy”. The Lancet Neurology 11 (2011): 969-977.
  36. Gaspar JM., et al. “Inside the diabetic brain: role of different players involved in cognitive decline”. ACS Chemical Neuroscience 2 (2016): 131-142.
  37. Puig KL., et al. “Amyloid precursor protein and proinflammatory changes are regulated in brain and adipose tissue in a murine model of high fat dietinduced obesity”. PLoS One1 (2012): e30378.
  38. America Diabetes Association. “Standards of Medical Care in Diabetes-2017”. Diabetes Care 40 (2017): S1-S142.
  39. Westermark P., et al. “Islet amyloid polypeptide, islet amyloid, and diabetes mellitus”. Physiological Reviews 91 (2011): 795-826.
  40. Sun Y., et al. “Metabolism: A Novel Shared Link between Diabetes Mellitus and Alzheimer's Disease”. Journal of Diabetes Research (2020): 4981814.
  41. An Y., et al. “Evidence for brain glucose dysregulation in Alzheimer’s disease”. Alzheimer's and Dementia 3 (2018): 318-329.
  42. De la Monte SM., et al. “The 20-Year Voyage Aboard the Journal of Alzheimer’s Disease: Docking at ‘Type 3 Diabetes’, Environmental/Exposure Factors, Pathogenic Mechanisms, and Potential Treatments”. Journal of Alzheimer's Disease 3 (2018): 1381-1390.
  43. Kleinridders A., et al. “Insulin action in brain regulates systemic metabolism and brain function”. Diabetes 63 (2014): 2232-2243.
  44. Raikwar SP., et al. “Are Tanycytes the Missing Link Between Type 2 Diabetes and Alzheimer's Disease”. Molecular Neurobiology 2 (2019): 833-843.
  45. Prasad S., et al. “Diabetes mellitus and blood-brain barrier dysfunction: an overview”. Journal of Pharmacovigilance 2 (2014): 125.
  46. Akter K., et al. “Diabetes mellitus and Alzheimer’s disease: shared pathology and treatment?” British Journal of Clinical Pharmacology 71 (2011): 365-376.
  47. Zhang J., et al. “An updated metaanalysis of cohort studies: diabetes and risk of Alzheimer's disease”. Diabetes Research and Clinical Practice 124 (2017): 41-47.
  48. Reijmer YD., et al. “Cognitive dysfunction in patients with type 2 diabetes”. Diabetes/Metabolism Research and Reviews 26 (2010): 507-519.
  49. Li W and Huang E. “An Update on Type 2 Diabetes Mellitus as a Risk Factor for Dementia”. Journal of Alzheimer's Disease 2 (2016): 393-402.
  50. Kim HG. “Cognitive dysfunctions in individuals with diabetes mellitus”. Yeungnam University Journal of Medicine 3 (2019): 183-191.
  51. Verma N and Despa F. “Contributing Factors to Diabetic Brain Injury and Cognitive Decline”. Diabetes and Metabolism Journal 5 (2019): 560-567.
  52. Li R., et al. “Effects and Underlying Mechanisms of Bioactive Compounds on Type 2 Diabetes Mellitus and Alzheimer's Disease”. Oxidative Medicine and Cellular Longevity (2019): 8165707.
  53. Chornenkyy Y., et al. “Alzheimer's disease and type 2 diabetes mellitus are distinct diseases with potential overlapping metabolic dysfunction upstream of observed cognitive decline”. Brain Pathology 1 (2019): 3-17.
  54. Wassenaar TM., et al. “Associations between modifiable risk factors and white matter of the aging brain: insights from diffusion tensor imaging studies”. Neurobiology of Aging 80 (2019): 56-70.
  55. Biessels GJ and Whitmer RA. “Cognitive dysfunction in diabetes: how to implement emerging guidelines”. Diabetologia1 (2020): 3-9.
  56. Sridhar GR., et al. “Emerging links between type 2 diabetes and Alzheimer's disease”. World Journal of Diabetes 5 (2015): 744-751.
  57. Biessels GJ., et al. “Dementia and cognitive decline in type 2 diabetes and prediabetic stages: Towards targeted interventions”. The Lancet Diabetes and Endocrinology 2 (2014): 246-255.
  58. Novak V., et al. “Enhancement of vasoreactivity and cognition by intranasal insulin in type 2 diabetes”. Diabetes Care 37 (2014): 751-759.
  59. Benedict C and Grillo CA. “Insulin Resistance as a Therapeutic Target in the Treatment of Alzheimer's Disease: A State-of-the-Art Review”. Frontiers in Neuroscience 12 (2018): 215.
  60. Messier C and Teutenberg K. “The role of insulin, insulin growth factor, and insulin-degrading enzyme in brain aging and Alzheimer's disease”. Neural Plasticity 12 (2005): 311-328.
  61. Butterfield DA and Halliwell B. “Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease”. Nature Reviews Neuroscience3 (2019): 148-160.
  62. Sickmann HM and Waagepetersen HS. “Effects of diabetes on brain metabolism--is brain glycogen significant player?” Metabolic Brain Disease1 (2015): 335-343.
  63. Knopman DS., et al. “18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons”. Neurobiology of Aging9 (2014): 2096-2106.
Citation: Edgardo Gabriel Reich., et al. “Brain, Diabetes and Cognition”. EC Neurology 12.8 (2020): 116-129.

PubMed Indexed Article


EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005


EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777


EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347


EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478


EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253


EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033


EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992


EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505


EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793


EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211


EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047


EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560


EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318


EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819


EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840


EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344


EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476


EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658


EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489


EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278


EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108


EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571


EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333


EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883


EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001


EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937


EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723


EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726


EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603


EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646


EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616


EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290


EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226


EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812


EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268


News and Events


December Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the December issue of respective journals and the latest articles can be viewed on the current issue pages.

Submission Deadline for Upcoming Issue

ECronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before December 20, 2021.

Certificate of Publication

ECronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

ECronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.

Immediate Assistance

The prime motto of this team is to clarify all the queries without any delay or hesitation to avoid the inconvenience. For immediate assistance on your queries please don't hesitate to drop an email to editor@ecronicon.uk